Oxidative Stress and Neurobiology of Demyelination

Molecular Neurobiology

Volumn 53, Issue 1, 2016, Pages 744-758

  Ljubisavljevic, Srdjan ^a,b  

^a Clinical Center Ni   (Serbia)

^b UNIVERSITY OF NI   (Serbia)

Author keywords

Neuroinflammation; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED OXIDATION PROTEIN PRODUCT; ALPHA TOCOPHEROL; ASCORBIC ACID; BILIRUBIN; CATALASE; GLUTATHIONE; INTERSTITIAL COLLAGENASE; PROTEINASE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; AUTACOID;

ALLERGIC ENCEPHALOMYELITIS; BLOOD BRAIN BARRIER; CALCIUM TRANSPORT; DISEASE SEVERITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; GENE EXPRESSION; HUMAN; LIPID PEROXIDATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN HOMEOSTASIS; REVIEW; ANIMAL; DEMYELINATING DISEASE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; DEMYELINATING DISEASES; HUMANS; INFLAMMATION MEDIATORS; LIPID PEROXIDATION; OXIDATIVE STRESS;

EID: 84953362271     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-9041-x     Document Type: Review

References (198)

1. Ames AI (2000) CNS energy metabolism as related to function. Brain Res Rev 34:42–68
2. Galea I, Bechmann I, Perry VH (2007) What is immune privilege (not)? Trends Immunol 28:12–18
3. Abbott NJ, Ronnback L, Hansson E (2006) Astrocyte–endothelial interactions at the blood–brain barrier. Nat Rev Neurosci 7:41–53
4. Bailey SL, Carpentier PA, McMahon EJ, Begolka WS, Miller SD (2006) Innate and adaptive immune responses of the central nervous system. Crit Rev Immunol 26:149–188
5. Owens T, Bechmann I, Engelhardt B (2008) Perivascular spaces and the two steps to neuroinflammation. J Neuropathol Exp Neurol 67:1113–1121
6. Chan WY, Kohsaka S, Rezaie P (2007) The origin and cell lineage of microglia: new concepts. Brain Res Rev 53:344–354
7. Block ML, Hong JS (2005) Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 76(2):77–98
8. Mrak RE, Griffin WS (2005) Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 26(3):349–354
9. Ladeby R, Wirenfeldt M, Garcia-Ovejero D, Fenger C, Dissing-Olesen L, Dalmau I, Finsen B (2005) Microglial cell population dynamics in the injured adult central nervous system. Brain Res Rev 48:196–206
10. Dheen ST, Kaur C, Ling EA (2007) Microglial activation and its implications in the brain diseases. Curr Med Chem 14:1189–1197
11. Fabriek BO, Van Haastert ES, Galea I, Polfliet MM, Dopp ED, Van Den Heuvel MM, Van Den Berg TK, De Groot CJ, Van DV, Dijkstra CD (2005) CD163 positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation. Glia 51:297–305
12. Rivest S (2009) Regulation of innate immune responses in the brain. Nat Rev Immunol 9(6):429–439
13. Kivisakk P, Imitola J, Rasmussen S, Elyaman W, Zhu B, Ransohoff RM, Khoury SJ (2009) Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. Ann Neurol 65:457–469
14. Fetler L, Amigorena S (2005) Brain under surveillance: the microglia patrol. Science 309:392–393
15. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H (2009) The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132(5):1175–1189
16. Schnell L, Fearn S, Klassen H, Schwab ME, Perry VH (1999) Acute inflammatory responses to mechanical lesions in the CNS: differences between brain and spinal cord. Eur J Neurosci 11:3648–3658
17. Ponomarev ED, Shriver LP, Maresz K, Dittel BN (2005) Microglial cell activation and proliferation precedes the onset of CNS autoimmunity. J Neurosci Res 81:374–389
18. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343:938–952
19. Hafler DA (2004) Multiple sclerosis. J Clin Invest 113:788–94
20. Rizvi SI, Maurya PK (2007) Alterations in antioxidant enzymes during aging in humans. Mol Biotechnol 37:58–61
21. van Horssen J, Schreibelt G, Drexhage J, Hazes T, Dijkstra CD, van der Valk P, de Vries HE (2008) Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic Biol Med 45(12):1729–1737
22. Tasset I, Agüera E, Sánchez-López F, Feijóo M, Giraldo AI, Cruz AH, Gascón F, Túnez I (2012) Peripheral oxidative stress in relapsing-remitting multiple sclerosis. Clin Biochem 45(6):440–444
23. Ullevig S, Kim HS, Asmis R (2013) S-glutathionylation in monocyte and macrophage (dys)function. Int J Mol Sci 14(8):15212–15232
24. Erden Inal M, Kanbak G, Sunal E (2001) Antioxidant enzyme activities and malondialdehyde levels related to aging. Clin Chim Acta 305:75–80
25. Schreibelt G, van Horssen J, van Rossum S, Dijkstra CD, Drukarch B, de Vries HE (2007) Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology. Brain Res Rev 56(2):322–330
26. Miller AF (2004) Superoxide dismutases: active sites that save, but a protein that kills. Curr Opin Chem Biol 8(2):162–168
27. Namaki S, Mohsenzadegan M, Mirshafiey A (2009) Superoxide dismutase: a light horizon in treatment of multiple sclerosis. J Chin Clin Med 4(10):585–591
28. Afonso V, Champy R, Mitrovic D, Collin P, Lomri A (2007) Reactive oxygen species and superoxide dismutases: role in joint disease. Joint Bone Spine 74:324–329
29. Johnson F, Giulivi C (2005) Superoxide dismutases and their impact upon human health. Mol Aspects Med 26(4–5):340–52
30. Ramming T, Appenzeller-Herzog C (2013) Destroy and exploit: catalyzed removal of hydroperoxides from the endoplasmic reticulum. Int J Cell Biol 2013:180906
31. Woolley JF, Stanicka J, Cotter TG (2013) Recent advances in reactive oxygen species measurement in biological systems. Trends Biochem Sci 38(11):556–565
32. Piloni NE, Fermandez V, Videla LA, Puntarulo S (2013) Acute iron overload and oxidative stress in brain. Toxicology 314(1):174–182
33. Korbecki J, Baranowska-Bosiacka I, Gutowska I, Chlubek D (2013) The effect of reactive oxygen species on the synthesis of prostanoids from arachidonic acid. J Physiol Pharmacol 64(4):409–421
34. Ozyazgan S, Andican G, Erman H, Tuzcu A, Uzun H, Onal B, Ozyazgan Y (2013) Relation of protein oxidation parameters and disease activity in patients with Behçet’s disease. Clin Lab 59(7–8):819–825
35. Feligioni M, Nisticò R (2013) SUMO: a (oxidative) stressed protein. Neuromolecular Med 15(4):707–719
36. Sitar ME, Aydin S, Cakatay U (2013) Human serum albumin and its relation with oxidative stress. Clin Lab 59(9–10):945–952
37. Sadowska-Bartosz I, Adamczyk-Sowa M, Galiniak S, Mucha S, Pierzchala K, Bartosz G (2013) Oxidative modification of serum proteins in multiple sclerosis. Neurochem Int 63(5):507–516
38. Go YM, Jones DP (2013) Thiol/disulfide redox states in signaling and sensing. Crit Rev Biochem Mol Biol 48(2):173–181
39. Boersma BJ, D’Alessandro T, Benton MR, Kirk M, Wilson LS, Prasain J, Botting NP, Barnes S, Darley-Usmar VM, Patel RP (2003) Neutrophil myeloperoxidase chlorinates and nitrates soy isoflavones and enhances their antioxidant properties. Free Radic Biol Med 35(11):1417–1430
40. Perez Gutierrez RM, Flores Cotera LB, Gonzalez AM (2012) Evaluation of the antioxidant and anti-glycation effects of the hexane extract from piper auritum leaves in vitro and beneficial activity on oxidative stress and advanced glycation end-product-mediated renal injury in streptozotocin-treated diabetic rats. Molecules 17(10):11897–11919
41. Ferretti G, Bacchetti T (2011) Peroxidation of lipoproteins in multiple sclerosis. J Neurol Sci 311(1–2):92–97
42. Nam TG (2011) Lipid peroxidation and its toxicological implications. Toxicol Res 27(1):1–6
43. Yeagle PL (2013) Non-covalent binding of membrane lipids to membrane proteins. Biochim Biophys Acta. doi:10.1016/j.bbamem.2013.11.009
44. Ren R, Hashimoto T, Mizuno M, Takigawa H, Yoshida M, Azuma T, Kanazawa K (2013) A lipid peroxidation product 9-oxononanoic acid induces phospholipase A2 activity and thromboxane A2 production in human blood. J Clin Biochem Nutr 52(3):228–233
45. Koch M, Mostert J, Arutjunyan AV, Stepanov M, Teelken A, Heersema D, De Keyser J (2007) Plasma lipid peroxidation and progression of disability in multiple sclerosis. Eur J Neurol 14(5):529–533
46. Quintana FJ, Yeste A, Weiner HL, Covacu R (2012) Lipids and lipid-reactive antibodies as biomarkers for multiple sclerosis. J Neuroimmunol 248(1):53–57
47. Pandey KB, Rizvi SI (2009) Protective effect of resveratrol on formation of membrane protein carbonyls and lipid peroxidation in erythrocytes subjected to oxidative stress. Appl Physiol Nutr Metab 34:1093–1097
48. Mitosek-Szewczyk K, Gordon-Krajcer W, Walendzik P, Stelmasiak Z (2010) Free radical peroxidation products in cerebrospinal fluid and serum of patients with multiple sclerosis after glucocorticoid therapy. Folia Neuropathol 48(2):116–122
49. Pandey KB, Rizvi SI (2010) Protective effect of resveratrol on markers of oxidative stress in human erythrocytes subjected to in vitro oxidative insult. Phytother Res 24(S1):S11–S14
50. Sims-Robinson C, Hur J, Hayes JM, Dauch JR, Keller PJ, Brooks SV, Feldman EL (2013) The role of oxidative stress in nervous system aging. PLoS One 8(7):e68011
51. Sarsour EH, Louise Kalen A, Goswami P (2013) Manganese superoxide dismutase regulates a redox cycle within the cell cycle. Antioxid Redox Sign. doi:10.1089/ars.2013.5303
52. Sheng Y, Chattopadhyay M, Whitelegge J, Valentine JS (2012) SOD1 aggregation and ALS: role of metallation states and disulfide status. Curr Top Med Chem 12(22):2560–2572
53. Mirshafiey A, Mohsenzadegan M (2009) Antioxidant therapy in multiple sclerosis. Immunopharmacol Immunotoxicol 31(1):13–29
54. Carillon J, Rouanet JM, Cristol JP, Brion R (2013) Superoxide dismutase administration, a potential therapy against oxidative stress related diseases: several routes of supplementation and proposal of an original mechanism of action. Pharm Res 30(11):2718–2728
55. Qi X, Hauswirth WW, Guy J (2007) Dual gene therapy with extracellular superoxide dismutase and catalase attenuates experimental optic neuritis. Mol Vis 13:1–11
56. Heather LM, Teismann P (2009) Glutathione—a review on its role and significance in Parkinson’s disease. FASEB J 23(10):3263–3272
57. Baud O, Greene AE, Li J, Wang H, Volpe JJ, Rosenberg PA (2004) Glutathione peroxidase-catalase cooperativity is required for resistance to hydrogen peroxide by mature rat oligodendrocytes. J Neurosci 24:1531–1540
58. Keller JN, Dimayuga E, Chen Q, Thorpe J, Gee J, Ding Q (2004) Autophagy, proteasomes, lipofuscin, and oxidative stress in the aging brain. Int J Biochem Cell Biol 36:2376–2391
59. Halldorsdottir SM, Kristinsson HG, Sveinsdottir H, Thorkelsson G, Hamaguchi PY (2013) The effect of natural antioxidants on haemoglobin-mediated lipid oxidation during enzymatic hydrolysis of cod protein. Food Chem 141(2):914–919
60. Penga F, Yanga Y, Liua J, Jianga Y, Zhua C, Denga X, Hua X, Chena X, Zhongb X (2012) Low antioxidant status of serum uric acid, bilirubin and albumin in patients with neuromyelitis optica. Eur J Neurol 19:277–283
61. Han MH, Hwang SI, Roy DB, Lundgren DH, Price JV, Ousman SS, Fernald GH, Gerlitz B, Robinson WH, Baranzini SE, Grinnell BW, Raine CS, Sobel RA, Han DK, Steinman L (2008) Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 451(7182):1076–1081
62. Pitt D, Werner P, Raine CS (2000) Glutamate excitotoxicity in a model of multiple sclerosis. Nature Med 6:67–70
63. Lambeth JD (2004) NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 4:181–189
64. Ilhan A, Akyol O, Gurel A, Armutcu F, Iraz M, Oztas E (2004) Protective effects of caffeic acid phenethyl ester against experimental allergic encephalomyelitis-induced oxidative stress in rats. Free Radic Biol Med 37:386–394
65. Witte ME, Bo L, Rodenburg RJ, Belien JA, Musters R, Hazes T, Wintjes LT, Smeitink JA, Geurts JJ, De Vries H, Van DV, van Horssen J (2009) Enhanced number and activity of mitochondria in multiple sclerosis lesions. J Pathol 219:193–204
66. Pahan K, Mondal S (2012) Crosstalk between nitric oxide and T helper cells. J Clin Cell Immunol 3:e109
67. Satoh T, Lipton SA (2007) Redox regulation of neuronal survival mediated by electrophilic compounds. Trends Neurosci 1:37–45
68. Yokoyama H, Yano R, Aoki E, Kato H, Araki T (2008) Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice. Metab Brain Dis 23:335–349
69. Charil A, Filippi M (2007) Inflammatory demyelination and neurodegeneration in early multiple sclerosis. J Neurol Sci 259:7–15
70. Macco R, Pelizzoni I, Consonni A, Vitali I, Giacalone G, Martinelli Boneschi F, Codazzi F, Grohovaz F, Zacchetti D (2013) Astrocytes acquire resistance to iron-dependent oxidative stress upon proinflammatory activation. J Neuroinflamm 10(1):130
71. Ortiz GG, Pacheco-Moisés FP, Bitzer-Quintero OK, Ramírez-Anguiano AC, Flores-Alvarado LJ, Ramírez-Ramírez V, Macias-Islas MA, Torres-Sánchez ED (2013) Immunology and oxidative stress in multiple sclerosis: clinical and basic approach. Clin Dev Immunol 2013:708659
72. Ljubisavljevic S, Stojanovic I (2014) Neuroinflammation and demyelination from the point of nitrosative stress as a new target for neuroprotection. Rev Neurosci. doi:10.1515/revneuro-2014-0060
73. Garden GA, Moller T. Microglia biology in health and disease. J. Neuroimmune. Pharmacol. 2006; 1: 127–137
74. Kornek B, Storch M, Weissert R, Wallstroem E, Stefferl A, Olsson T, Linington C, Schmidbauer M, Lassmann H (2000) Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive and remyelinated lesions. Amer J Pathol 157:267–276
75. Androdias G, Reynolds R, Chanal M, Ritleng C, Confavreux C, Nataf S (2010) Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords. Ann Neurol 68:465–476
76. Knoferle J, Koch JC, Ostendorf T, Michel U, Planchamp V, Vutova P, Tönges L, Stadelmann C, Brück W, Bähr M, Lingor P (2010) Mechanisms of acute axonal degeneration in the optic nerve in vivo. Proc Natl Acad Sci U S A 107:6064–6069
77. Shah D, Kiran R, Wanchu A, Bhatnagar A (2010) Oxidative stress in systemic lupus erythematosus: relationship to Th1 cytokine and disease activity. Immunol Lett 129:7–12
78. Fukuda M, Kanou F, Shimada N, Sawabe M, Saito Y, Murayama S, Hashimoto M, Maruyama N, Ishigami A (2009) Elevated levels of 4-hydroxynonenal-histidine Michael adduct in the hippocampi of patients with Alzheimer’s disease. Biomed Res 30:227–233
79. Miller E, Mrowicka M, Saluk-Juszczak J, Ireneusz M (2011) The level of isoprostanes as a non-invasive marker for in vivo lipid peroxidation in secondary progressive multiple sclerosis. Neurochem Res 36(6):1012–1016
80. Hendrickx DA, Koning N, Schuurman KG, van Strien ME, van Eden CG, Hamann J, Huitinga I (2013) Selective upregulation of scavenger receptors in and around demyelinating areas in multiple sclerosis. J Neuropathol Exp Neurol 72(2):106–118
81. Zhu X, Su B, Wang X, Smith MA, Perry G (2007) Causes of oxidative stress in Alzheimer disease. Cell Mol Life Sci 64:2202–2210
82. Xiang W, Weisbach V, Sticht H, Seebahn A, Bussmann J, Zimmermann R, Becker CM (2013) Oxidative stress-induced posttranslational modifications of human hemoglobin in erythrocytes. Arch Biochem Biophys 529:34–44
83. Oliveira SR, Kallaur AP, Simao ANC, Morimoto HK, Lopes J, Panis C, Petenucci DL, da Silva E, Cecchini R, Kaimen-Maciel DR, Reiche EM (2012) Oxidative stress in multiple sclerosis patients in clinical remission: association with the expanded disability status scale. J Neurol Sci 321(1–2):49–53
84. Przedborski S, Ischiropoulos H (2005) Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson’s disease. Antioxid Redox Signal 7:685–693
85. Kim SU, Park YH, Min JS, Sun HN, Han YH, Hua JM, Lee TH, Lee SR, Chang KT, Kang SW, Kim JM, Yu DY, Lee SH, Lee DS (2013) Peroxiredoxin I is a ROS/p38 MAPK-dependent inducible antioxidant that regulates NF-κB-mediated iNOS induction and microglial activation. J Neuroimmunol 259(1–2):26–36
86. Singh I, Paintlia AS, Khan M, Stanislaus R, Paintlia MK, Haq E, Singh AK, Contreras MA (2004) Impaired peroxisomal function in the central nervous system with inflammatory disease of experimental autoimmune encephalomyelitis animals and protection by lovastatin treatment. Brain Res 1022(1–2):1–11
87. Zeis T, Graumann U, Reynolds R, Schaeren-Wiemers N (2008) Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. Brain 131:288–303
88. Sullivan GM, Mierzwa AJ, Kijpaisalratana N, Tang H, Wang Y, Song SK, Selwyn R, Armstrong RC (2013) Oligodendrocyte lineage and subventricular zone response to traumatic axonal injury in the corpus callosum. J Neuropathol Exp Neurol 72(12):1106–1125
89. Fancy SP, Kotter MR, Harrington EP, Huang JK, Zhao C, Rowitch DH, Franklin RJ (2010) Overcoming remyelination failure in multiple sclerosis and other myelin disorders. Exp Neurol 225:18–23
90. Chaitanya GV, Omura S, Sato F, Martinez NE, Minagar A, Ramanathan M, Guttman BW, Zivadinov R, Tsunoda I, Alexander JS (2013) Inflammation induces neuro-lymphatic protein expression in multiple sclerosis brain neurovasculature. J Neuroinflamm 10(1):125
91. Agrawal SM, Williamson J, Sharma R, Kebir H, Patel K, Prat A, Yong VW (2013) Extracellular matrix metalloproteinase inducer shows active perivascular cuffs in multiple sclerosis. Brain 136(6):1760–1777
92. Uccelli A, Pedemonte E, Narciso E, Mancardi G (2003) Biological markers of the inflammatory phase of multiple sclerosis. Neurol Sci 24(5):S271–274
93. Willard SS, Koochekpour S (2013) Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications. Int J Biol Sci 9(7):728–742
94. Mandolesi G, Musella A, Gentile A, Grasselli G, Haji N, Sepman H, Fresegna D, Bullitta S, De Vito F, Musumeci G, Di Sanza C, Strata P, Centonze D (2013) Interleukin-1β alters glutamate transmission at Purkinje cell synapses in a mouse model of multiple sclerosis. J Neurosci 33(29):12105–12121
95. Arend C, Brandmann M, Dringen R (2013) The antiretroviral protease inhibitor ritonavir accelerates glutathione export from cultured primary astrocytes. Neurochem Res 38(4):732–741
96. Fernandez-Fernandez S, Almeida A, Bolaños JP (2012) Antioxidant and bioenergetic coupling between neurons and astrocytes. Biochem J 443(1):3–11
97. Bizzozero OA, Ziegler JL, De Jesus G, Bolognani F (2006) Acute depletion of reduced glutathione causes extensive carbonylation of rat brain proteins. J Neurosci Res 83(4):656–667
98. Rumzan R, Wang JJ, Zeng C, Chen X, Li Y, Luo T, Lv F, Wang ZP, Hou H, Huang F (2013) Iron deposition in the precentral grey matter in patients with multiple sclerosis: a quantitative study using susceptibility-weighted imaging. Eur J Radiol 82(2):95–99
99. Abo-Krysha N, Rashed L (2008) The role of iron dysregulation in the pathogenesis of multiple sclerosis: an Egyptian study. Mult Scler J 14(5):602–608
100. Besler HT, Comoglu S (2003) Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis. Nutr Neurosci 6:189–196
101. Salemi G, Gueli MC, Vitale F, Battaglieri F, Guglielmini E, Ragonese P, Trentacosti A, Massenti MF, Savettieri G, Bono A (2010) Blood lipids, homocysteine, stress factors, and vitamins in clinically stable multiple sclerosis patients. Lipids Health Dis 9:19–21
102. Wallberg M, Bergquist J, Achour A, Breij E, Harris RA (2007) Malondialdehyde modification of myelin oligodendrocyte glycoprotein leads to increased immunogenicity and encephalitogenicity. Eur J Immunol 37:1986–1995
103. Ljubisavljevic S, Stojanovic I, Pavlovic D, Milojkovic M, Sokolovic D, Stevanovic I, Petrovic A (2013) Suppression of the lipid peroxidation process in the CNS reduces neurological expression of experimentally induced autoimmune encephalomyelitis. Folia Neuropathol 51(1):51–57
104. Ljubisavljevic S, Stojanovic I, Vojinovic S, Stojanov D, Stojanovic S, Kocic G, Savic D, Cvetkovic T, Pavlovic D (2013) Cerebrospinal fluid and plasma oxidative stress biomarkers in different clinical phenotypes of neuroinflammatory acute attacks. Conceptual accession: from fundamental to clinic. Cell Mol Neurobiol 33(6):767–777
105. Bongarzone ER, Pasquini JM, Soto EF (1995) Oxidative damage to proteins and lipids of CNS myelin produced by in vitro generated reactive oxygen species. J Neurosci Res 41:213–221
106. Wuttge DM, Bruzelius M, Stemme S (1999) T-cell recognition of lipid peroxidation products breaks tolerance to self proteins. Immunology 98:273–279
107. Weismann D, Hartvigsen K, Lauer N, Bennett KL, Scholl HPN, Issa PC, Cano M, Brandstätter H, Tsimikas S, Skerka C, Superti-Furga G, Handa JT, Zipfel PF, Witztum JL, Christoph J (2011) Binder complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 478:76–81
108. Kalyvas A, David S (2004) Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease. Neuron 41:323–335
109. Marusic S, Leach MW, Pelker JW, Azoitei ML, Uozumi N, Cui J, Shen MW, DeClercq CM, Miyashiro JS, Carito BA, Thakker P, Simmons DL, Leonard JP, Shimizu T, Clark JD (2005) Cytosolic phospholipase A2α-deficient mice are resistant to experimental autoimmune encephalomyelitis. J Exp Med 202:841–851
110. Jana A, Pahan K (2007) Oxidative stress kills human primary oligodendrocytes via neutral sphingomyelinase: implications for multiple sclerosis. J Neuroimmune Pharmacol 2:184–193
111. Tavazzi B, Batocchi AP, Amorini AM, Nociti V, D’Urso S, Longo S, Gullotta S, Picardi M, Lazzarin G (2011) Serum metabolic profile in multiple sclerosis patients. Multiple Sclerosis International. doi:10.1155/2011/167156
112. Keles MS, Taysi S, Sen N, Aksoy H, Akçay F (2001) Effect of corticosteroid therapy on serum and CSF malondialdehyde and antioxidant proteins in multiple sclerosis. Can J Neurol Sci 28(2):141–143
113. Sbardella E, Greco A, Stromillo ML, Prosperini L, Puopolo M, Cefaro LA, Pantano P, De Stefano N, Minghetti L, Pozzilli C (2012) Isoprostanes in clinically isolated syndrome and early multiple sclerosis as biomarkers of tissue damage and predictors of clinical course. Mult Scler J. doi:10.1177/1352458512457721
114. Joseph JA, Shukitt-Hale B, Casadesus G, Fisher D (2005) Oxidative stress and inflammation in brain aging: nutritional considerations. Neurochem Res 30(6–7):927–935
115. Ferretti G, Bacchetti T, Principi F, Di Ludovico F, Viti B, Angeleri VA, Danni M, Provinciali L (2005) Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity. Mult Scler J 11:677–682
116. Tsuda K (2012) Associations of oxidative stress and inflammation and their role in the regulation of membrane fluidity of red blood cells in hypertensive and normotensive men: an electron spin resonance investigation. Adv Biosci Biotechnol 3:1020–1027
117. Hon GM, Hassan MS, van Rensburg SJ, Abel S, Marais DW, van Jaarsveld P, Smuts CM, Henning F, Erasmus RT, Matsha T (2009) Erythrocyte membrane fatty acids in patients with multiple sclerosis. Mult Scler J 15(6):759–762
118. Koch M, Ramsaransing GS, Arutjunyan AV, Stepanov M, Teelken A, Heersema DJ, De Keyser J (2006) Oxidative stress in serum and peripheral blood leukocytes in patients with different disease courses of multiple sclerosis. J Neurol 253:483–487
119. de Freitas MV, de Oliveira MR, dos Santos DF, de Cássia Mascarenhas Netto R, Fenelon SB, Penha-Silva N (2010) Influence of the use of statin on the stability of erythrocyte membranes in multiple sclerosis. J Membr Biol 233(1–3):127–134
120. Pasichna EP, Morozova RP, Donchenko HV, Vinychuk SM, Kopchak OO (2007) Lipid peroxidation and antioxidant defence enzyme activity in multiple sclerosis. Ukr Biokhim Zh 79(5):165–174
121. Miler E, Walczak A, Majsterek I, Kędziora J (2013) Melatonin reduces oxidative stress in the erythrocytes of multiple sclerosis patients with secondary progressive clinical course. J Neuroimmunol. doi:10.1016/j.jneuroim.2013.02.012
122. Vani R, Shiva CS, Devi SA (2002) Oxidative stress in erythrocytes: a study on the effect of antioxidant mixtures during intermittent exposures to high altitude. Int J Biometeorol 54(5):553–562
123. Acar A, Ugur Cevik M, Evliyaoglu O, Uzar E, Tamam Y, Arıkanoglu A, Yucel Y, Varol S, Onder H, Taşdemir N (2012) Evaluation of serum oxidant/antioxidant balance in multiple sclerosis. Acta Neurol Belg 112(3):275–280
124. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B (1996) Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49:1304–1313
125. Ghafourifar P, Mousavizadeh K, Parihar MS, Nazarewicz RR, Parihar A, Zenebe WJ (2008) Mitochondria in multiple sclerosis. Front Biosci 13:3116–3126
126. Fernandez O, Vermersch P (2011) From the fundamentals of multiple sclerosis to clinical management. J Neurol Sci 311:S1–2
127. Pentón-Rol G, Cervantes-Llanos M, Martínez-Sánchez G, Cabrera-Gómez JA, Valenzuela-Silva CM, Ramírez-Nuñez O, Casanova-Orta M, Robinson-Agramonte MA, Lopategui-Cabezas I, López-Saura PA (2009) TNF-α and IL-10 downregulation and marked oxidative stress in neuromyelitis optica. J Inflamm 6:18
128. Ljubisavljevic S, Stojanovic I, Vojinovic S, Stojanov D, Stojanovic S, Cvetkovic T, Savic D, Pavlovic D (2013) The patients with clinically isolated syndrome and relapsing remitting multiple sclerosis show different levels of advanced oxidation protein products and total thiol content in plasma and CSF. Neurochem Int 62(7):988–997
129. Park B, Lee S, Kim E, Cho K, Riddell SR, Cho S, Ahn K (2006) Redox regulation facilitates optimal peptide selection by MHC class I during antigen processing. Cell 127:369–382
130. Heinecke JW, Li W, Daehnke HD, Goldstein JA (1993) Dityrosine, a specific marker of oxidation, in synthesized by the myeloperoxidase hydrogen peroxide system of human neutrophils and macrophages. J Biol Chem 268:4069–4077
131. Davies U (1987) Protein damage and degradation by oxygen radicals. I. General aspects. J Biol Chem 262:9895–9901
132. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707–717
133. Lucas M, Rodríguez MC, Gata JM, Zayas MD, Solano F, Izquierdo G (2003) Regulation by interferon beta-1a of reactive oxygen metabolites production by lymphocytes and monocytes and serum sulfhydryls in relapsing multiple sclerosis patients. Neurochem Int 42:67–71
134. Frohman EM, Racke MK, Raine CS (2006) Multiple sclerosis—the plaque and its pathogenesis. N Engl J Med 354:942–55
135. Bramow S, Frischer JM, Lassmann H, Koch-Henriksen N, Lucchinetti CF, Sorensen PS, Laursen H (2010) Demyelination versus remyelination in progressive multiple sclerosis. Brain 133:2983–2998
136. Bisaga GN, Odinak MM, Boiko AN, Melnik YB, Popova NF (2012) Treatment of exacerbations of multiple sclerosis without the use of corticosteroids: the role of metabolic and antioxidant therapy. Neurosci Behav Physiol 42(2):123–127
137. Bjartmar C, Trapp BD (2001) Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 14:271–278
138. De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia MC, Antel JP, Matthews PM, Arnold DL (2001) Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 58:65–70
139. Pandey KB, Rizvi SI (2012) Markers of oxidative stress in erythrocytes and plasma during aging in humans. Oxid Med Cell Longev 3(1):2–12
140. Fiorini A, Koudriavtseva T, Bucaj E, Coccia R, Foppoli C, Giorgi A, Schininà ME, Di Domenico F, De Marco F, Perluigi M (2013) Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis. PLoS One 8(6):e65184
141. Shelton MD, Mieyal JJ (2008) Regulation by reversible S-glutathionylation: molecular targets implicated in inflammatory diseases. Mol Cell 25:332–346
142. Garcia J, Han D, Sancheti H, Yap LP, Kaplowitz N, Cadenas E (2010) Regulation of mitochondrial glutathione redox status and protein glutathionylation by respiratory substrates. J Biol Chem 285:39646–39654
143. Lu SC (2009) Regulation of glutathione synthesis. Mol Aspects Med 30:42–59
144. Castegna A, Palmieri L, Spera I, Porcelli V, Palmieri F, Fabis-Pedrini MJ, Kean RB, Barkhouse DA, Curtis MT, Hooper DC (2011) Oxidative stress and reduced glutamine synthetase activity in the absence of inflammation in the cortex of mice with experimental allergic encephalomyelitis. Neuroscience 185:97–105
145. Tao F, Lu SD, Zhang LM, Huang YL, Sun FY (2001) Role of excitatory amino acid transporter 1 in neonatal rat neuronal damage induced by hypoxia-ischemia. Neuroscience 102(3):503–513
146. ¯ as a neuroprotective drug target. CNS Neurol Disord Drug Targets 9(3):373–382
147. Werner P, Pitt D, Raine CS (2001) Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 50(2):169–180
148. Calabrese V, Scapagnini G, Ravagna A, Bella R, Foresti R, Bates TE, Giuffrida Stella AM, Pennisi G (2002) Nitric oxide synthase is present in the cerebrospinal fluid of patients with active multiple sclerosis and is associated with increases in cerebrospinal fluid protein nitrotyrosine and S-nitrosothiols and with changes in glutathione levels. J Neurosci Res 70:580–587
149. Moss DW, Bates TE (2001) Activation of murine microglial cell lines by lipopolysaccharide and interferon-γ causes NO-mediated decreases in mitochondrial and cellular function. Eur J Neurosci 13:529–538
150. Kronke M, Adam-Klages S (2002) Role of caspases in TNF-mediated regulation of cPLA2. FEBS Lett 531:18–22
151. Pautz A, Art J, Hahn S, Nowag S, Voss C, Kleinert H (2010) Regulation of the expression of inducible nitric oxide synthase. Nitric Oxide 23(2):75–93
152. Steinert JR, Chernova T, Forsythe ID (2010) Nitric oxide signaling in brain function, dysfunction, and dementia. Neuroscientist 16:435–452
153. Ouyang M, Shen X (2006) Critical role of ASK1 in the 6- hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells. J Neurochem 97:234–244
154. Whiteman M, Chua YL, Zhang D, Duan W, Liou YC, Armstrong JS (2006) Nitric oxide protects against mitochondrial permeabilization induced by glutathione depletion: role of S-nitrosylation? Biochem Biophys Res Commun 339:255–262
155. Paige JS, Xu G, Stancevic B, Jaffrey SR (2008) Nitrosothiol reactivity profiling identifies S-nitrosylated proteins with unexpected stability. Chem Biol 15:1307–1316
156. Romero JM, Bizzozero OA (2009) Intracellular glutathione mediates the denitrosylation of protein nitrosothiols in the rat spinal cord. J Neurosci Res 87:701–709
157. Marozkina NV, Gaston B (2011) S-Nitrosylation signaling regulates cellular protein interactions. Biochim Biophys Acta. doi:10.1016/j.bbagen.2011.06.017
158. Motterlini R, Foresti R, Bassi R, Calabrese V, Clark JE, Green CJ (2000) Endothelial heme oxygenase-1 induction by hypoxia. Modulation by inducible nitric-oxide synthase and S-nitrosothiols. J Biol Chem 275:13613–13620
159. Muller B, Kleschyov AL, Alencar JL, Vanin A, Stoclet JC (2002) Nitric oxide transport and storage in the cardiovascular system. Ann NY Acad Sci 962:131–139
160. Kim SF, Huri DA, Snyder SH (2005) Inducible nitric oxide synthase binds, S-nitrosylates and activates cyclooxygenase-2. Science 310:1966–1970
161. Knott AB, Bossy-Wetzel E (2009) Nitric oxide in health and disease of the nervous system. Antioxid Redox Signal 11:541–53
162. Liu L, Yan Y, Zeng M, Zhang J, Hanes MA, Ahearn G, McMahon TJ, Dickfeld T, Marshall HE, Que LG, Stamler JS (2004) Essential roles of S-nitrosothiols in vascular homeostasis and endotoxic shock. Cell 116:617–628
163. Foster MW, McMahon TJ, Stamler JS (2003) S-Nitrosylation in health and disease. Trends Mol Med 9:160–168
164. Witherick J, Wilkins A, Scolding N, Kemp K (2010) Mechanisms of oxidative damage in multiple sclerosis and a cell therapy approach to treatment. Autoimmune Diseases. doi:10.4061/2011/164608
165. Liu JS, Zhao ML, Brosnan CF, Lee SC (2001) Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol 158:2057–2066
166. Sparaco M, Gaeta LM, Tozzi G, Bertini E, Pastore A, Simonati A, Santorelli FM, Piemonte F (2006) Protein glutathionylation in human central nervous system: potential role in redox regulation of neuronal defense against free radicals. J Neurosci Res 83:256–263
167. Boullerne AI, Rodrıguez JJ, Touil T, Brochet B, Schmidt S, Abrous NR, Le Moal M, Pua JR, Jensen MA, Mayo W, Arnason BGW, Petry KG (2002) Anti-S-nitrosocysteine antibodies are a predictive marker for demyelination in experimental autoimmune encephalomyelitis: implications for multiple sclerosis. J Neurosci 22(1):123–132
168. Khan M, Sekhon B, Giri S, Jatana M, Gilg AG, Ayasolla K, Elango C, Singh AK, Singh I (2005) S-Nitrosoglutathione reduces inflammation and protects brain against focal cerebral ischemia in a rat model of experimental stroke. J Cereb Blood Flow Metab 25(2):177–192
169. Hendriks JJ, Teunissen CE, De Vries HE, Dijkstra CD (2005) Macrophages and neurodegeneration. Brain Res Rev 48:185–195
170. Ischiropoulos H, Beckman JS (2003) Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J Clin Invest 111:163–169
171. Foster MW, Hess DT, Stamler JS (2009) Protein S-nitrosylation in health and disease: a current perspective. Trends Mol Med 15:391–404
172. Ljubisavljevic S, Stojanovic I, Pavlovic R, Stojnev S, Stevanovic I, Sokolovic D, Pavlovic D (2012) The reduced glutathione and S-nitrosothiols levels in acute phase of experimental demyelination—pathophysiological approach and possible clinical relevancy. Neuroscience 219:175–182
173. Prasad R, Giri S, Nath N, Singh I, Singh AK (2007) GSNO attenuates EAE disease by S-nitrosylation-mediated modulation of endothelial-monocyte interactions. Glia 55:65–77
174. Richter-Addo GB, Legzdins P, Burstyn J (2002) Introduction: nitric oxide chemistry. Chem Rev 102(4):857–860
175. Jomova K, Vondrakova D, Lawson M, Valko M (2010) Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 345(1–2):91–104
176. Kidd PM (2001) Multiple sclerosis, an autoimmune inflammatory disease: prospects for its integrative management. Altern Med Rev 6:54066
177. Grinberg L, Fibach E, Amer J, Atlas D (2005) N-acetylcysteine amide, a novel cell-permeating thiol, restores cellular glutathione and protects human red blood cells from oxidative stress. Free Radical Bio Med 38:1136–1145
178. Deneke SM (2000) Thiol-based antioxidants. Curr Top Cell Regul 36:151–180
179. Hvaring C, Vujicic S, Aasly JO, Feinstein DL, White LR, Boullerne AI (2013) IgM to S-nitrosylated protein is found intrathecally in relapsing-remitting multiple sclerosis. J Neuroimmunol 256(1–2):77–83
180. Lin SX, Lisi L, Dello Russo C, Polak PE, Sharp A, Weinberg G, Kalinin S, Feinstein DL (2011) The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro 3(2):75–84. doi:10.1042/AN20100033
181. Nath N, Morinaga O, Singh I (2010) S-nitrosoglutathione a physiologic nitric oxide carrier attenuates experimental autoimmune encephalomyelitis. J Neuroimmune Pharm 2:240–251
182. Staron A, Makosa G, Koter-Michalak M (2012) Oxidative stress in erythrocytes from patients with rheumatoid arthritis. Rheumatol Int 32:331–334
183. Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, Giuffrida Stella AM (2003) Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res 28(9):1321–1328
184. Scapagnini G, Foresti R, Calabrese V, Giuffrida Stella AM, Green CJ, Motterlini R (2002) Caffeic acid phenethyl ester and curcumin: a novel class of heme oxygenase-l inducers. Mol Pharmacol 61:554–561
185. Stojanovic I, Ljubisavljevic S, Stevanovic I, Pavlovic R, Cvetkovic T, Djordjevic V, Pavlovic D, Vojinovic S, Basic J (2012) Nitric oxide-mediated signalization and nitrosative stress in neuropathology. J Med Biochem 31(4):295–300
186. van Meeteren ME, Teunissen CE, Dijkstra CD, van Tol EAF (2005) Antioxidants and polyunsaturated fatty acids in multiple sclerosis. Eur J Clin Nutr 59:1347–1361
187. Ljubisavljevic S, Stojanovic I, Cvetkovic T, Vojinovic S, Stojanov D, Stojanovic D, Bojanic V, Stokanovic D, Pavlovic D (2014) The glutathione homeostasis disruption of erythrocytes, but not glutathione peroxidase activity changes, is closely accompanied with neurological and radiological scoring of acute CNS inflammation. Neuroimmunomodulation 21:13–20
188. Adamczyksowa M, Sowa P, Pierzchala K, Polaniak R, Labuzroszak B (2012) Antioxidative enzymes activity and malondialdehyde concentration. During mitoxantrone therapy in multiple sclerosis patients. J Physiol Pharmacol 63(6):683–690
189. Miller E, Mrowicka M, Zołyński K, Kedziora J (2009) Oxidative stress in multiple sclerosis. Pol Merkur Lekarski 162:499–502
190. Straif D, Werz DO, Kellner R, Bahr U, Steinhilber D (2000) Glutathione peroxidase-1 but not -4 is involved in the regulation of cellular 5-lipoxygenase activity in monocytic cells. Biochem J 349:455–461
191. Jana A, Hogan EL, Pahan K (2009) Ceramide and neurodegeneration: susceptibility of neurons and oligodendrocytes to cell damage and death. J Neurol Sci 278(1):5–15
192. Liu Y, Hao W, Letiembre M, Walter S, Kulanga M, Neumann H, Fassbender K (2006) Suppression of microglial inflammatory activity by myelin phagocytosis: role of p47-PHOX-mediated generation of reactive oxygen species. J Neurosci 26(50):12904–12913
193. van Horssen J, Witte ME, Schreibelt G, de Vries HE (2011) Radical changes in multiple sclerosis pathogenesis. BBA – Mol Basis Dis 1812(2):141–150
194. Tajouri L, Mellick AS, Ashton KJ, Tannenberg AEG, Nagra RM, Tourtellotte WW, Griffiths LR (2003) Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. Mol Brain Res 119(2):170–183
195. Yoshida E, Mokunoa K, Aoki S, Takahashi A, Riku S, Murayama T, Yanagi T, Kato K (1994) Cerebrospinal fluid levels of superoxide dismutases in neurological diseases detected by sensitive enzyme immunoassays. J Neurol Sci 124:25–31
196. Gallan PM, Carrascosa A, Gussinye M, Dominguez C (2003) Biomarkers of diabetes associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complication. Free Radical Bio Med 34:1563–1574
197. Zagórski T, Dudek I, Berkan L, Mazurek M, Kedziora J, Chmielewski H (1991) Superoxide dismutase (SOD-1) activity in erythrocytes of patients with multiple sclerosis. Neurol Neurochir Pol 25(6):725–730
198. Rowiński R, Kozakiewicz M, Kędziora-Kornatowska K, Hübner-Woźniak E, Kędziora J (2013) Markers of oxidative stress and erythrocyte antioxidant enzyme activity in older men and women with differing physical activity. Exp Gerontol 48:1141–1146